Prevision Medicine announced the expansion of its proprietary personalized drug screening platform, PrevisionOne™, to include Multiple Myeloma (MM).
Currently designed for research-use-only (RUO), the test supports oncologists to rapidly identify the most effective treatment combinations for each individual MM patient. The test generates patient-specific drug sensitivity profiles, aiding faster, data-driven therapeutic decisions in the treatment of MM patients. Following the successful launch of its drug screening solutions for Acute Myeloid Leukemia and Glioblastoma, Prevision Medicine continues to expand its platform into additional high-need indications.
